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T cell receptor (TCR) γδ-expressing T lymphocytes compose evolutionarily 
conserved cells with paradoxical features.  On the one hand, clonally expanded γδ T 
cells with unique specificities typify adaptive immunity. Conversely, large TCRγδ+ 
intraepithelial lymphocyte (γδ IEL) compartments exhibit limited TCR diversity and 
effect rapid, innate-like tissue surveillance.  The development of several γδ IEL 
compartments depends upon epithelial Btnl/BTNL (butyrophilin-like) genes, which 
are members of the B7-superfamily of T cell co-stimulators.  Here we show that 
Btnl/BTNL responsiveness is mediated by germline-encoded motifs within the 
cognate TCRVγ chains of mouse and human γδ IEL. This contrasts with diverse 
antigen recognition by clonally-restricted complementarity-determining regions 
(CDRs) 1-3 of TCRγδ.  Hence, TCRγδ intrinsically combines innate and adaptive 
immunity by utilizing spatially distinct regions to discriminate non-clonal agonist-
selecting elements from clone-specific ligands.  The broader implications for antigen 





Adaptive immunity in jawed vertebrates is underpinned by the use of somatic gene 
rearrangement to diversify three conserved lineages of lymphocytes: αβ T cells, B 
cells and γδ T cells1. Prima facie, TCRγδ	 has high intrinsic diversity, and major 
expansions of unique γδ T cell clones have been described, with cytomegalovirus 
(CMV) a candidate driver2, 3, 4.  
 
Nonetheless, microbe-specific	γδ T cells have proved largely elusive. Instead, human 
peripheral blood γδ T cells make generic responses to microbes by recognizing 
hydroxymethylbut-2-enyl pyrophosphate (HMBPP), an intermediate in sterol 
metabolism that is more akin to a pathogen-associated molecular pattern5.  Indeed, 
HMBPP-reactive cells also respond to endogenous sterol intermediates, e.g. 
isopentenyl pyrophosphate (IPP), upregulated in virus-infected or transformed cells5,5.	
Likewise, the TCR specificities of rare or unique mouse and human γδ T cells are 
seemingly enriched in self-encoded ligands, several of which are closely related to 
Major Histocompatibility Complex (MHC) proteins6, 7, 8, 9, 10, 11.  Until the biological 
significance of such specificities is established, the host benefits of adaptive γδ TCR 
diversification will remain unresolved.  
 
In contrast to clonally-restricted reactivities, the Vγ5Vδ1 TCR of murine dendritic 
epidermal T cells (DETC) is quasi-monoclonal. Likewise, most murine intestinal IEL 
express Vγ712, 13, 14.  Such extra-lymphoid γδ T cells exhibit hallmarks of innate 
immunity, in providing rapid, non-clonal responses to local tissue dysregulation15, 16, 
17, 18. The acquisition of innate-like properties by T cells has been associated with 
agonist selection during development19,  in which regard, Vγ5+ DETC development 
depends on Skint1, a Btnl gene expressed by thymic epithelial cells and suprabasal 
keratinocytes20, 21.  Likewise, Vγ7+ IEL development depends on Btnl1 expressed by 
enterocytes22.  Moreover, consistent with Btnl/BTNL proteins functioning as 
heteromers23, Vγ7+ IEL respond specifically to cells co-expressing Btnl1 and Btnl6.  
Indicative of a conserved biology, human colonic γδ T cells specifically respond to 
cells co-expressing the enterocyte proteins, BTNL3 and BTNL822. 
 
Btnl/BTNL proteins sit within the B7-superfamily, whose members link innate and 
adaptive immunity by communicating the prevailing pathophysiologic milieu (e.g. the 
presence of microbes) to lymphocyte co-receptors, such as CD2816.   As an example, 
Skint1 structurally resembles PD-L1, a B7-related ligand for the PD1 inhibitory co-
receptor24.  Hence, Btnl/BTNL proteins might likewise regulate γδ Τ cells via co-
receptors.  Conversely, the strict associations of Btnl/BTNL proteins with γδ TCR 
usage might reflect their acting directly via the TCR.   Indeed, TCR Vγ9Vδ2-
mediated HMBPP/IPP responses are BTN3A1+BTN3A2-dependent23, 25.  The 
prospect that some γδ TCRs might be specific for monomorphic, self-encoded 
proteins while others show clonally-restricted reactivities has provoked the view that 
there are both innate and adaptive γδ T cells26.   
 
Here we offer a different perspective, in showing that signature, murine and human 
intestinal γδ TCRs are sufficient to confer responsiveness to discrete, Btnl/BTNL 
proteins. However, the response is mediated by a germline-encoded segment of Vγ 
that neither contributes to nor obviously precludes antigen-binding to clonally-
restricted CDRs. Thus, individual γδ TCRs have an intrinsic capacity to combine 
innate and adaptive immunity consistent with the multifaceted biology of γδ T cells. 
RESULTS 
Murine TCRVγ7 mediates Btnl-responsiveness 
The signature intestinal γδ IEL compartment is dominated by Vγ7+ cells, whose 
development is severely impaired in Btnl1-/- mice22. To assess the diversity of Btnl1-
dependent Vγ7+ cells, a small-scale TCR deep-sequencing analysis22 was expanded, 
revealing that Vγ7CDR3 varied in length (from 10-15 amino acids) and slightly in 
sequence composition (Fig. 1a).  TCRδ chain usage was diverse, mostly comprising 
four gene segments, particularly when only unique reads were counted so as to correct 
for clonal expansions: Trdv2-2 (encoding the Vδ4 chain recognized by monoclonal 
antibody GL227); Trdv7; Trdv6D-1 and Trdv6D-2 (Fig. 1b). In each case, CDR3δ 
length and composition were highly diverse (Fig. 1c).  Of note, Vγ7- IELs, which are 
a minor fraction of gut γδ T cells and are Btnl1-independent, showed largely 
comparable Vδ chain usage, albeit that Trdv1 and Trdv5 were relatively enriched 
(Supplementary Fig. 1a).  In sum, deep sequencing revealed Vγ7 gene segment usage 
to be the sole constant property of Btnl1-dependent IEL.    
 
When MODE-K murine intestinal epithelial cells were transduced with Btnl1 and 
Btnl6, the gene products showed stoichiometric co-immunoprecipitation 
(Supplementary Fig. 1b), in relation to which primary Vγ7+ IEL specifically down-
regulate their TCRs when co-cultured with MODE-K Btnl1+Btnl6-transductants 
(MODE-K.l1l6 hereafter), but not with MODE-K cells transduced with either Btnl1 or 
Btnl6 alone or with empty vector (MODE-K.EV)22.   To explore the basis of this, co-
cultures were optimized such that >50% of Vγ7+ IEL upregulated CD25 (IL-2Rα 
chain), of which most cells downregulated CD122 (the interleukin 15 (IL-15) receptor 
β chain), downregulated the TCR by ~40%, and upregulated CD71 (the transferrin 
receptor) relative to cells co-cultured with MODE-K.EV (Fig. 1d-f). Such phenotypic 
changes are typical for T cells experiencing TCR engagement28.  
 
Based on the clear discrimination between Btnl1+6-responsive and non-responsive 
Vγ7+ IEL offered by this assay, we performed single cell flow cytometry-sorting of 
responding cells, and (informed by the deep sequencing data) subjected them to gene 
amplification with TCRVγ7, Vδ7, Vδ2-2 and Vδ6D1/2 primers, followed by 
sequencing. Consistent with the deep sequencing data, the forty-three TCRγ/δ pairs 
obtained showed Vγ7CDR3 lengths of 12-15 amino acids, paired to unique clones of 
Vδ7 (n=25), Vδ2-2 (n=13) and Vδ6D1/2 (n=5) with diverse CDR3δ lengths and 
sequences (Supplementary Table 1). Vγ7+ IEL diversity was evident in the uniqueness 
of each γ/δ pairing, although some limits were suggested by our finding that ~25% of 
recovered TCRδ sequences were also identified in the deep sequencing data-sets 
derived from three independent IEL harvests (Supplementary Table 1). 
 
Capturing this TCR diversity, we stably transduced J76 cells, a human TCR-deficient 
T cell line that can be used to assay TCR bio-activities29, with seven Vγ7Vδ pairs, 
mo1-mo7, that collectively spanned three different Vδ chains, with six being 
represented in the deep sequencing data-sets (Table 1).   Each pairing was efficiently 
and comparably expressed on the cell surface, as was a control Vγ5Vδ1 DETC TCR, 
termed moD (Fig. 2a). When incubated with anti-CD3ε, a TCR cross-linking agent, 
J76-mo1 through J76-mo7 cells showed substantial TCR downregulation relative to 
transductants cultured with isotype-control antibody (Fig. 2b, c). The expression of 
CD25 and CD122 by J76 cells were not reliably modulated by anti-CD3ε, precluding 
their use as read-outs of TCR responsiveness.  However, all transductants upregulated 
CD69 in response to anti-CD3ε, albeit variably (Fig. 2b, c). Of note, TCR 
downregulation occurs rapidly in response to TCR engagement, whereas CD69 
upregulation is a downstream event, which segregated qualitatively but not 
quantitatively with TCR downregulation (Fig. 2c).  
 
J76-mo1 through J76-mo7 cells phenocopied primary Vγ7+ IEL by showing TCR 
downregulation of ~35% to >50% upon co-culture with MODE-K.l1l6 cells but not 
MODE-K.EV cells (Fig. 2b, c). In all cases, CD69 was upregulated, again correlating 
qualitatively rather than quantitatively with TCR downregulation (Fig.2b, c).  
Conversely, Vγ5Vδ1+ J76-moD cells showed neither TCR downregulation nor CD69 
upregulation when co-cultured with MODE-K.l1l6 cells (Fig. 2b, c).  However, 
responsiveness to MODE-K.l1l6 cells was qualitatively restored for J76-mo5.Vδ1 
cells expressing a variant of moD in which the Vγ5 chain was replaced with the mo5 
Vγ7 chain (the most common Vγ7 sequence in the three deep-sequencing analyses) 
(Table 1) (Fig. 2c).  The fact that J76-mo5.Vδ1 cells responded less well than J76-
mo5 cells (Fig 2c) most likely reflected the fact that the Vδ1 chain (encoded by the 
Trdv4 gene) never ordinarily pairs with Vγ7:  indeed, there was no Trdv4 read in the 
deep-sequencing data of sorted Vγ7+ cells (Fig. 1b). From these results, we conclude 
that different IEL-derived Vγ7+ TCRs are sufficient to make human J76 cells 
qualitatively responsive to mouse Btnl1+6, largely irrespective of Vδ usage and 
CDR3γ/δ composition. Nonetheless, different, comparably expressed Vγ7+ TCRs 
showed quantitative variation in responsiveness both to Btnl1+6 and to anti-CD3ε 
(Fig. 2c).   
 
The comparable kinetics of CD69 upregulation by J76-mo5 cells stimulated with 
either MODE-K.l1l6 cells or anti-CD3ε (Supplementary Fig. 2a) further suggested 
that the Vγ7-dependent responses reflected TCR engagement. Likewise, NR4A1, a 
signature TCR-responsive gene encoding the transcription factor Nur7730 was 
substantially and significantly upregulated by J76-mo5 cells exposed to anti-CD3ε or 
MODE-K.l1l6 cells, but not to MODE-K.EV cells (Fig. 2d), phenocopying the 
response of primary IEL from Nur77.eGFP transgenic mice22.   
 
To preclude that responsiveness to MODE-K.l1l6 cells reflected some unexplained 
facet of TCR-transduced J76 cells, we transduced mo1 and mo5 TCRs (Table 1) into 
TCR-deficient human JRT3 cells expressing an NFAT activation-dependent 
luciferase31. Following co-culture with MODE-K.l1l6 cells, but not MODE-K.EV 
cells, JRT3-mo1 and JRT3-mo5 cells showed TCR downregulation, CD69 
upregulation, and induced luciferase activity: conversely, no such responses were 
shown by Vγ5Vδ1+ JRT3-moD cells (Supplementary Fig. 2b).   Similarly, exposure 
to anti-CD3ε or to MODE-K.l1l6 cells provoked IL-2 secretion as well as moderate 
TCR downregulation and CD69 upregulation by the Jurkat subclone E6.1 transduced 
with mo5 (Supplementary Fig. 2c).   In sum, the capacity of the mouse Vγ7+ mo5 
TCR to confer Btnl1+6 responsiveness to several human T cell lines strongly 
suggested that reactivity was mediated by the TCR itself.  Moreover, J76-mo5 cells, 
J76-mo1 cells, and primary Vγ7+ IEL responded to Btnl1+6 expressed by live or fixed 
cells, and by cells of different origins (human gut [MODE-K] and kidney [293T]; 
hamster ovary [CHO]; mouse skin [PAM2.12]) (Supplementary Fig. 2d-g), making it 
unlikely that the Vγ7+ TCR-mediated response was to undefined molecule(s) co-
expressed with Btnl1+6. 
 
TCR-mediated BTNL-responsiveness is conserved 
Like their Vγ7+ mouse counterparts, human colonic γδ T cells located primarily to the 
IEL compartment (Fig. 3a) and responded ex vivo to 293T cells specifically co-
transduced with human BTNL3+BTNL8, primarily expressed by gut epithelial cells22. 
To investigate the basis of this responsiveness, we optimized the co-culture of 
primary colonic T cells with BTNL3+8-expressing 293T cells (293T.L3L8 hereafter).  
Across several healthy donors, the predominant gut γδ T cell population, reactive to 
an antibody specific for Vγ2, Vγ3 and Vγ4 chains32 (Supplementary Fig. 3a), showed 
consistent TCR downregulation of ~45%, and variable CD25 upregulation relative to 
cells incubated with 293T.EV cells (Fig. 3b; Supplementary Fig. 3b).  These 
responses were not observed in colonic Vγ2/3/4- γδ T cells, Vδ2+ T cells (typical of 
blood γδ cells) or αβ T cells (Fig. 3b; Supplementary Fig. 3b).   
 
This optimized assay permitted BTNL3+8 responsive γδ T cells to be single cell-
sorted based on TCR downregulation (Donor 1) or TCR downregulation and CD25 
upregulation (Donors 2 and 3) (Fig. 3c). The nineteen TCRγδ pairs (hu1-hu19) 
recovered from the BTNL3+8 responsive cells were dominated by Vγ4 chains (17/19) 
with variable CDR3 composition and length (from 9-14 amino acids), paired to either 
Vδ1 (12/19) or Vδ3 (7/19) chains displaying highly diverse CDR3s (Table 2).  
Although all 19 recovered sequences were unique, ~50% were identified in the deep 
sequencing data sets, albeit at different frequencies (Table 2).  
 
Three Vγ4Vδ1+ TCR pairs - hu7, hu12, and hu17 - displaying diverse CDR3γ/δ 
sequences and ranging from high abundance to very rare in the deep-sequencing reads 
(Table 2), were cloned and used to transduce J76 cells (hereafter J76-hu7, J76-hu12, 
J76-hu17), while a peripheral blood-derived Vγ9Vδ2 TCR was used to generate a 
control cell line, J76-huPB.  Displaying reasonably comparable levels of surface 
expression (Supplementary Fig. 3c), J76-hu7, J76-hu12, and J76-hu17 cells showed 
pronounced TCR downregulation in response to anti-CD3ε or co-culture with 
293T.L3L8 cells, but not 293T.EV cells (Fig. 3d, e).  CD69 was likewise upregulated, 
although the magnitude varied across the three transductants in response to 
293T.L3L8 cells or anti-CD3ε (Fig. 3d,e).  Conversely, J76-huPB cells showed 
neither TCR downregulation nor CD69 upregulation (Fig. 3e).  Of note, TCR 
downregulation by J76-hu transductants responding to 293T.L3L8 cells was usually 
greater than that shown by J76-mo transductants responding to MODE-K.l1l6 cells 
(compare Fig 2c and Fig 3e), possibly reflecting the differential signaling modalities 
of human and mouse γδTCRs33.   
 
J76-hu12 cells responded to BTNL3+8 expressed by different cell types, including 
human J76 T cells and murine MODE-K cells (Supplementary Fig. 3d). Likewise, 
JRT3 cells (see above) transduced with hu12 showed NFAT activation-dependent 
luciferase activity following exposure to either 293T.L3L8 cells or PMA+ionomycin, 
whereas control Vγ9Vδ2+ JRT3.huPB cells responded only to PMA+ionomycin 
(Supplementary Fig. 3e). These data indicated that the constant feature of BTNL3+8 
responsive cells was Vγ4. 
 
BTNL-responsiveness requires TCR FR3/HV4 
Two of the 19 TCRγδ pairs recovered from the single-cell sorted, BTNL-responsive 
human colonic γδ Τ cells expressed Vγ2, which differs from Vγ4 by only nine amino 
acids (Fig. 4a). It was therefore important to test whether Vγ2 could also confer 
BTNL3+8 responsiveness, or whether the recovery of Vγ2+ TCRs was from cells 
stochastically expressing low TCR levels during the sort.  To this end, J76 cells were 
transduced with a modified version of hu17 (hu17.Vγ2) in which  the Vγ4 gene 
segment was substituted with the Vγ2 chain, while preserving CDR3γ and the same 
Vδ1 chain (Supplementary Fig. 4a).  The resultant transductants showed neither TCR 
downregulation nor CD69 upregulation in response to co-culture with 293T.L3L8 
cells (Fig. 4b and Supplementary Fig. 4b).  
 
Three of the amino acid differences between Vγ2 and Vγ4 map to CDR1 and CDR2 
(Fig. 4a). Therefore, J76 cells were transduced with modified versions of hu17 in 
which Vγ4 CDR1 and/or CDR2 were replaced with the counterpart Vγ2 sequences 
(hu17.Vγ2CDR1; hu17.Vγ2CDR2; and hu17.Vγ2CDR1+2) (Supplementary Fig 4a). Upon 
co-culture with 293T.L3L8 cells, the resulting transductants showed TCR 
downregulation and CD69 upregulation comparable to J76-hu17 cells (Fig. 4b and 
Supplementary Fig. 4b), indicating that the failure of Vγ2 to respond to BTNL3+8 did 
not map to the CDRs.  
 
Vγ2 also differs from Vγ4 by four amino acids in a sub-region of framework region 3 
(FR3) known as “hypervariable region 4” (HV4) because of its variability among 
different antigen receptors (Fig 4a).  When J76 cells were transduced with a modified 
version of hu17 in which Vγ2HV4 (KYYTYASTRNNLRLIL, hereafter referred to as 
YANL) (Supplementary Fig. 4a) replaced the Vγ4 counterpart 
(KYDTYGSTRKNLRMIL, hereafter DGKM), the resulting transductants 
(hu17DGKM>YANL cells) showed neither TCR downregulation nor CD69 upregulation 
in response to 293T.L3L8 cells (Fig. 4c and Supplementary Fig. 4c), pinpointing the 
importance of HV4.   
 
Of the four amino acids distinguishing Vγ4HV4 from Vγ2HV4 (DGKM versus YANL), 
exchanging only the two most N-terminal residues (hu17.DG>YA) was sufficient to 
abrogate BTNL3+8 responsiveness, whereas exchanging the remaining two residues 
(hu17.KM>NL) (Supplementary Fig. 4a) was well tolerated (Fig. 4c and Supplementary 
Fig. 4c).  Reciprocally, inserting DG from Vγ4HV4 in place of YA in Vγ2HV4 
(hu17.Vγ2YA>DG) (Supplementary Fig. 4a) was sufficient to confer strong BTNL3+8- 
responsiveness on J76-hu17.Vγ2YA>DG cells (Fig. 4d and Supplementary Fig. 4d).   
The Vγ3 gene segment is further diverged from Vγ4 than is Vγ2 (Fig. 4a). Thus, J76-
hu17.Vγ3 cells transduced with a variant of hu17 in which Vγ3 was substituted for 
Vγ4 predictably failed to show TCR downregulation or CD69 upregulation CD69 
when co-cultured with 293T.L3L8 cells  (Fig. 4d and Supplementary Fig. 4a, d).   
However, J76-hu17.Vγ3-Vγ4HV4 cells, in which Vγ3HV4 was replaced by Vγ4HV4 
partially recovered responsiveness (Fig. 4d and Supplementary Fig. 4a, d).  
Completely consistent results were obtained in parallel when NFAT-dependent 
luciferase activity was measured in JRT3 cells transduced with hu17, hu17DG>YA, 
hu17.Vγ2, hu17.Vγ2YA>DG, hu17.Vγ3, and hu17.Vγ3-Vγ4HV4 (Supplementary Fig. 4e).  
Collectively these results show that the N-terminal portion of Vγ4HV4 was necessary 
and sufficient for transduced T cells to respond to 293T.L3L8 cells, although its 
potency was evidently modified by other sequences within the Vγ gene segment. 
The role of FR3/HV4 is evolutionarily conserved 
Next we investigated the basis of the Btnl1+6 responsiveness of mouse Vγ7 TCRs. 
Although mouse Vγ genes differ greatly from each other, Vγ6 shares some similarities 
with Vγ7, in particular the properties of the amino acids surrounding the CDRs and 
the length of the serine-rich CDR2 (Fig. 5a).   Therefore, J76 cells were transduced 
with mo5.Vγ6, in which Vγ7 was replaced with Vγ6, while still retaining the Vγ7CDR3 
(Fig 5a). J76-mo5.Vγ6 cells expressed the Vγ6Vδ2-2 TCR at the cell surface, albeit at 
slightly lower levels than J76-mo5 cells (Supplementary Fig. 5a, b), but they neither 
downregulated the TCR nor upregulated CD69 in response to MODE-K.l1l6 cells 
(Fig. 5b and Supplementary Fig. 5b).  In contrast, cells transduced with mo5.Vγ6CDR1 
in which the Vγ7CDR1 (RTGTY) was replaced with Vγ6CDR1 (TSVQKPDAY) (Fig 5a) 
showed only partially reduced Btnl1+6 responsiveness relative to J76-mo5 cells  (Fig. 
5b and Supplementary Fig. 5a, b).  Btnl1+6 responsiveness was also retained, albeit 
reduced, when mo5 Vγ7CDR2 (YNFVSSTT) was substituted with Vγ6CDR2 (SSSKENI) 
(mo5.Vγ6CDR2), or when both CDR1 and CDR2 of Vγ7 were replaced by the 
equivalent regions from Vγ6 (mo5.Vγ6CDR1+2) (Fig.5a,b and Supplementary Fig. 5a, 
b).  In sum, CDR1 and CDR2 residues were not essential for Btnl1+6 responsiveness.  
 
Because mouse Vγ7 is more closely related to human Vγ4 and Vγ2 than to any other 
mouse Vγ gene, sequence alignment allowed us to identify four residues, (H,E,K,F) in 
mouse Vγ7HV4 (KYHVYEGPDKRYKFVL) that corresponded to the four residues 
(D,G,K,M) at which human Vγ4HV4 differed from Vγ2HV4 (Supplementary Fig. 5c), 
two of which (D and G) were shown to be essential for BTNL3+8 responsiveness (see 
Fig 4c).  Based on this, J76 cells were transduced with a construct (mo5HEF>DGM) in 
which the mouse Vγ7 residues, HEKF, were replaced with their human Vγ4 
counterparts, DGKM (Supplementary Fig. 5c). When co-cultured with MODE-K.l1l6 
cells, these J76-mo5HEF>DGM cells showed neither TCR downregulation nor CD69 
upregulation (Fig 5c and Supplementary Fig. 5d).  Likewise, mo5 constructs carrying 
single amino acid exchanges between Vγ7HV4 and human Vγ4HV4 (mo5H>D and 
mo5E>G) (Supplementary Fig. 5c) identified two residues (H and E) in the N-terminal 
portion of Vγ7HV4 that were essential for responding to Btnl1+6 (Fig. 5c and 
Supplementary Fig. 5d), and that occupied equivalent positions to the two 
determinants (D and G) of human Vγ4 responsiveness to BTNL3+8.   Indeed, 
whereas replacement of Vγ7HV4 in mo5 with human Vγ4HV4 (mo5-huVγ4HV4) 
(Supplementary Fig 5c) abrogated Btnl1+6 responsiveness, there was a compensatory 
gain of responsiveness (TCR downregulation and CD69 upregulation) toward cells 
expressing human BTNL3+8 (Fig. 5d).  Thus, BTNL/Btnl responsiveness is 
determined by FR3/HV4 motifs whose positioning is evolutionarily conserved, and 
which are functionally interchangeable. 
 
BTNL3 and Btnl6 CFG faces interact with HV4 
The molecular structure of the human Vγ4Vδ1 TCR (PDB 4MNG)7 revealed that 
HV4 formed a solvent-exposed loop (Supplementary Fig. 6a). Because we 
occasionally observed TCR downregulation and CD69 upregulation in co-cultures of 
Vγ4Vδ1 transductants with 293T.L3 cells but never with 293T.L8 cells (Fig. 6a), we 
investigated whether the Vγ4 HV4 loop might mediate responses to solvent-exposed 
residues of BTNL3 versus BTNL8. To this end, a model for the BTNL3+8 dimer was 
derived from the X-ray structure of a BTN3A1 homodimer (PDB 4F80)34 using an in-
house homology program, 3D-JIGSAW35 (Supplementary Fig. 6b). Second, for each 
modeled chain, sequence alignments allowed beta-strand demarcation (A, B, C, C’, 
C”, D, E, F) according to the convention for Ig superfamily members (Supplementary 
Fig. 6c, d). Third, candidate solvent-exposed motifs that differed between the N-
terminal IgV-domains of BTNL3 and BTNL8 were identified as: NQFHA/GQFSS; 
EDWESK/KDQPFM; WF/RI; and DEEAT/YQKAI in the C, C”, F, and G strands, 
respectively (Fig. 6b, Supplementary Fig. 6c). Fourth, unrestricted docking 
simulations between Vγ4 and the BTNL3 IgV-domain using the in-house, publicly 
available docking server SwarmDock36 produced solutions converging on an 
interaction of Vγ4HV4 with the CFG face of BTNL3 (Supplementary Fig. 6e) that 
harbors three of the sets of residues distinguishing BTNL3 from BTNL8. Of note, Ig-
fold CFG faces are established mediators of protein-protein interactions37.   
 
Based on these findings, HA-tagged BTNL8 was co-expressed in 293T cells with 
either FLAG-tagged BTNL3 or with each of four FLAG-tagged BTNL3 constructs in 
which the candidate C, C’’, F, and G motifs were replaced with counterpart BTNL8 
sequences (L3GQFSS, L3KDQPFM, L3RI, L3YQKAI) (Fig 6c). Although each was 
comparably expressed (Supplementary Fig. 6f), only 293T.L3L8 cells and 
293T.L3KDQPFML8 cells would induce TCR downregulation and CD69 upregulation in 
co-cultured J76-hu17 cells (Fig 6c).  These results, together with the solutions offered 
by SwarmDock (above), permitted us to propose a refined docked complex in which 
unique residues in the CFG face of BTNL3 mediated functional interactions with 
Vγ4HV4 (Fig. 6d). 
 
Recombinant, monomeric, human Vγ4Vδ2 or Vγ4Vδ1 soluble TCRs (sTCRs), but 
neither Vγ2Vδ1 nor Vγ8Vδ1 sTCRs, showed dose-dependent staining of 293.L3L8 
cells but  not of 293T.EV cells (Fig. 6e,f), indicating that TCR Vγ4 can interact 
specifically and directly with BTNL3+8.  Consistent with this, the Vγ4Vδ2 and 
Vγ4Vδ1 sTCRs specifically stained mouse MODE-K.L3L8 cells (Supplementary Fig. 
6g).  Of note, the lower mean fluorescence intensity of MODE-K.L3L8 staining 
relative to 293T.L3L8 cell staining correlated with the relative expression of 
BTNL3+8 on the two cell types (Supplementary Fig. 6h).  
 
Next, we identified motifs on the CFG faces of mouse Btnl1 and Btnl6 corresponding 
to the BTNL3 residues that interact with Vγ4HV4 (Supplementary Fig. 6i,j). 
Thereupon, we generated 293T cells co-expressing Btnl1 with either Btnl6 or each of 
three mutants in which the Btnl6 C, F, G strand residues were replaced by their Btnl1 
counterparts (l6AQPTP, l6Q, l6SQEVS) (Fig 6g). Likewise we generated 293T cells co-
expressing Btnl6 with either Btnl1 or mutants in which the Btnl1 C, F, G strand 
residues were replaced by Btnl6 counterparts (l1SRFSA, l1H, l1YEEAI) (Fig 6g).  Only 
293T cells expressing wild type Btnl6 provoked TCR downregulation and CD69 
upregulation by co-cultured J76-mo5 cells, whereas 293T cells expressing mutant 
forms of Btnl6 did not (Fig. 6g and Supplementary Fig. 6k).  In sum, these results 
revealed that functional interactions with mouse TCRVγ7HV4 and human TCRVγ4HV4, 
respectively, were mediated by amino acid motifs in evolutionarily conserved 
positions on the C, F, G faces of Btnl6 and BTNL3, respectively. In both cases, the 
motifs mapped to only one of the two Btnl/BTNL chains required for activity. 
 
Human and mouse γδTCRs show dual reactivity  
The human Vγ4Vδ1 TCR structure used for modeling was previously shown to react 
to a CD1d-sulfatide complex, largely via Vδ1CDR1-3. According to our refined docked 
complex model (Fig. 6d), the Vγ4Vδ1 TCR could simultaneously engage CD1d-
sulfatide and BTNL3+8 expressed by the same cell (Fig. 7a). To further investigate 
this prospect of dual TCR-reactivity, we used a Vγ4Vδ5 TCR derived from LES, a 
human γδ T cell clone that responds to CMV-infected cells and to a spectrum of 
human carcinomas, including gut-derived HT29 cells8. These TCR-dependent 
responses are attributable to a unique specificity for a CD1-related protein, EPCR 
(endothelial protein C receptor), mediated largely by Vγ4CDR3.  
 
We found that JRT3 cells transduced with the LES TCR (JRT3-LES), but not JRT3-
hu12 cells showed significant, albeit low TCR downregulation and substantial CD69 
upregulation when co-cultured with either HT29 cells or 293T cells over-expressing 
EPCR (293T.EPCR) (Fig. 7b).  CD69 upregulation was completely or partially 
inhibited when the co-cultures were supplemented with an anti-EPCR antibody 
(Supplementary Fig. 7a).  By contrast, JRT3-LES and JRT3-hu12 cells both showed 
TCR downregulation and CD69 upregulation when co-cultured with 293T.L3L8 cells 
or 293T.EPCR+L3L8 cells, that each over-express BTNL3+8. Moreover, this 
response was unaffected by EPCR-reactive antibodies (Fig. 7b and Supplementary 
Fig. 7a).  Thus, JRT3-LES cells displayed a clonally-restricted TCR reactivity 
towards EPCR and a non-clonal TCR reactivity towards BTNL3+8.   
 
Relative to co-cultures with 293T.EV cells, JRT3-LES cells co-cultured with 
293T.EPCR, 293T.L3L8, or 293T.EPCR+L3L8 cells showed activation within 5 
minutes of PLC-γ and p-LAT, as judged by Western blotting (Supplementary Fig. 
7b), thereby indicating that activation via either of the LES TCR specificities (EPCR 
and BTNL3+8) could converge on equivalent downstream signaling pathways.    
Because the Vγ4Vδ5 LES TCR is blood-derived, the results also indicated that 
BTNL3+8 reactivity extended beyond gut-derived Vγ4 TCRs.  Indeed, J76 cells 
transduced with two human skin-derived Vγ4Vδ1 TCRs (sk1 and sk2) also showed 
TCR downregulation and CD69 upregulation when co-cultured with 293T.L3L8 cells 
(Supplementary Fig. 7c). Thus, seemingly irrespective of their tissue-of-origin, 
TCRVγ4 chains drove non-clonal responses to BTNL3+8. 
 
To examine if dual reactivity could be observed in primary intestinal γδ T cells from a 
healthy donor, colonic Vδ1+ IEL were sorted on the basis of binding to dextrameric 
multimers of CD1c complexed to phosphatidylcholine (CD1c-PC) (Supplementary 
Fig 7d). Of 24 Vδ1+ cells sorted and subjected to TCR sequencing, twenty one were 
Vγ5Vδ1+ and two were Vγ8Vδ1+, but one was Vγ4Vδ1+, from which the TCR (hu20) 
(Table 2) was used to transduce J76 cells. J76-hu20 cells, but not J76-hu17 cells could 
be stained specifically by CD1c-PC (Fig. 7c), whereas both cells lines showed strong 
responsiveness to 293T.L3L8 cells (Fig. 7d).  Thus, J76-hu20 cells showed clonally-
restricted TCR binding of CD1c-PC and non-clonal BTNL3+8 responsiveness.  
 
Lastly, we examined if dual reactivity also extended to primary mouse intestinal γδ 
IEL, ~0.5% of which reportedly bind to the MHC class I-related molecule T10-T22 
via a specific CDR3δ motif 6.  The same CDR3δ motif was found in the Vγ7Vδ7 
TCR of mo8 (clone 24, Supplementary Table 1), and J76-mo8 cells showed TCR 
downregulation and CD69 upregulation in response to cells over-expressing T22 
(MODE-K.T22; 293T.T22) as well as to cells over-expressing Btnl1+6 (MODE-
K.l1l6; 293T.l1l6; MODE-K.T22+l1l6; and 293T.T22+l1l6)  (Fig. 7e and 
Supplementary Fig. 7e). Moreover, Western blotting showed specific activation of 
PLCγ and pLAT in J76-mo8 cells co-cultured with MODE-K.l1l6, MODE-K.T22, 
and MODE-K.T22+l1l6 cells (Supplementary Fig. 7f). Conversely, J76-mo5 cells 
responded only to Btnl1+6-expressing cells (Fig. 7e). Thus, J76-mo8 cells showed 
clonally-restricted responsiveness to T22 and non-clonal TCR responsiveness to 
Btnl1+6.   Recognition by J76-mo8 cells of 293T.T22 cells (Fig. 7f) showed that the 
clonally-restricted response did not depend on Btnl1+6 proteins, since they were not 
expressed by 293T cells. 
	
DISCUSSION 
Here we identify an evolutionarily conserved mechanism by which the γδ TCR 
mediates the regulation of mouse and human intestinal γδ IELs by Btnl/BTNL 
proteins.  Murine Vγ7+ and human Vγ4+ TCRs were sufficient to confer qualitative 
responsiveness to Btnl1+6 and to BTNL3+8, respectively, whereas TCRs expressing 
different Vγ gene segments did not. Complementary loss-of-function and gain-of-
function experiments mapped Btnl/BTNL responsiveness to equivalent positions in 
the germline-encoded HV4 regions of mouse Vγ7 and human Vγ4, respectively.  
Thus, specific TCRVγ regions can use germline motifs to mediate responses to 
endogenous agonists, suggesting an innate interaction germane to the heritability of 
TCRVγ genes. 
 
Molecular modeling identified a means by which human Vγ4HV4 might interact 
directly with the CFG face of the N-terminal IgV domain of BTNL3. Supporting that 
model were mutagenesis studies that likewise implicated the CFG face of the Btnl6 
IgV domain in engaging mouse Vγ7HV4.  Of note, CFG faces mediate heterotypic 
interactions of numerous Ig superfamily proteins, including CD2, CD4, VCAM and 
MADCAM38, 39, 40, 41.   These results suggest a conserved mechanism whereby 
BTNL/Btnl regulation of γδ IEL is mediated by an “interacting chain” (Btnl6 or 
BTNL3) coupled to a “supporting chain” (Btnl1 or BTNL8) that jointly determine 
biological activity.  Moreover, this conservation may extend to the collaborative 
regulation by BTN3A1 and BTN3A2 of human peripheral blood γδ T cell responses 
to HMBPP23. 
 
Beyond the requirement for mouse Vγ7 and human Vγ4, respectively, Btnl/BTNL-
responsive γδ IEL are diverse, expressing various TCRδ chains with diverse CDR3s. 
According to the structural modeling, those clone-specific CDR3 regions could 
remain available to engage clonally-restricted antigens, irrespective of Btnl/BTNL 
engaging HV4.  Consistent with this, we demonstrated dual specificities for two 
human BTNL-responsive Vγ4 TCRs and for a murine Btnl-responsive Vγ7 TCR, with 
different sub-regions of the CDRs implicated in ligand binding 9,24.  Such spatially 
discrete dual specificities, involving HV4 and CDRs1-3, respectively, are distinct 
from commonly described cross-reactivities of CDR1-3 regions in other types of 
antigen receptor.  Rather, the γδ TCR has an intrinsic capacity to use a discrete 
germline-encoded region to mediate innate, non-clonal responses to an endogenous 
agonist, and recombinase-dependent regions to mediate adaptive, clone-specific 
responses to diverse ligands.  Clearly, these findings offer a framework for 
reconciling the innate-like biologies of γδ T cells with their adaptive, highly 
individual clonal dominance patterns2, 3, 4.   
 
BTNL/Btnl RNAs are seemingly expressed by differentiated enterocytes.  Thus, 
following γδ IEL selection Btnl/BTNL proteins might sustain steady-state interactions 
with neighbouring IEL, akin to tonic signaling that is proposed to sustain peripheral 
αβ T cell survival and/or competence42.  Indeed, steady-state ligand engagement by 
HV4 may induce in in primary IEL different signaling events to those induced by 
ligand binding to CRDs1-3.   In this regard, there is no evidence that Btnl/BTNL 
interactions determine peripheral clonal dominance; thus, fairly comparable responses 
to 293T.L3L8 cells were mediated by TCRs that were either highly abundant (e.g. 
hu12) or rare (e.g. hu7) in the deep sequencing data-set.  Conceivably, tonic signaling 
of αβ T cells may also be a “neutral event” that does not influence clonal dominance. 
 
Each of the clonally-restricted TCR antigens considered in this study is an MHC-
related molecule.  Although neither MHC nor CD1 molecules are required for γδ T 
cell repertoire development, their potential to function as clone-specific ligands is 
well established18, 43.  Several such ligands have been considered “stress-antigens”, 
promoting γδ T cell responses to dysregulated tissues, including cancer cells. Thus the 
γδ TCR might use HV4 to sense “normal self”, and CDR1-3 to sense “stressed self”, 
in which regard it is intriguing that Btnl/BTNL proteins are related to B7 proteins that 
communicate pathophysiologic contexts to regulate the responses of adaptive 
lymphocytes. In this context, the quasi-monomorphic DETC receptor may have a 
Btnl-like ligand at steady state (e.g. a Skint1 complex) and qualitatively distinct 
ligand(s) on dysregulated cells44.  
 
The apparently generalizable capacity of HV4 to form a solvent-exposed loop in 
γδTCRs raises the question as to whether it is broadly deployed to engage self-
agonists.  There is evidence for agonist selection of several γδ T cell subsets45, 46, and 
HV4-mediated agonist selection might in paritcular underpin the development of 
several tissue-associated γδ T cell compartments that are partly defined by restricted 
Vγ chain usage, and that effect different pre-programmed functions in response to 
myriad innate stimuli18.  Moreover, in cases where TCR signaling promoted cell death 
in developing γδ T cells47, it might be appropriate to evaluate whether this is also true 
for HV4-dependent signals.   
 
Likewise, our findings may have implications for TCRαβ+ NKT and MAIT cells 
which are partly defined by highly restricted TCRVα chain usage, and which undergo 
self-agonist selection prior to making rapid, polyclonal responses to innate stimuli, 
e.g. IL-12+IL-18.  Whereas selection depends upon determinants, such as CD1d-lipid 
complexes that bind TCRαβ CDRs48, 49, 50, the possible contribution(s) of HV4 may 
merit further study. Indeed, so-called “super-antigens”, which can profoundly 
influence αβ T cell repertoire development, mediate their effects by engaging 
TCRVβ-specific FR3 residues, including HV4, that transduce qualitatively distinct 
signals from those induced by CDR1-3 engagement51, 52, 53.  
 
Similarly, there might be a role(s) of HV4 in the antigen receptors of B1 B cells 
whose repertoires are seemingly shaped by agonist selection events that also drive the 
cells’ pre-programmed differentiation and association with non-lymphoid tissues54. 
FR3/HV4 residues of human Igs seem rarely to be implicated in foreign antigen 
binding, but were recently associated with high-affinity binding to auto-antigens in 
patients with central tolerance defects55.  Possibly this reflects a generalisable 
capacity of HV4 regions to engage endogenous ligands in a growing number of 




Human endoscopy biopsies were obtained from macroscopically healthy mucosa from 
the ascending colon of adult patients undergoing diagnostic colonoscopy after 
informed consent and in compliance with ethical approval (16/LO/0642) from the 
NHS Health Research Authority (London – Fulham Research Ethics Committee). 
 
Mice 
Wild-type (WT) C57Bl/6J mice were obtained from Jackson Laboratories and 
maintained at The Francis Crick Institute’s Biological resource facilities. Male mice 
aged between 3 and 5 weeks were used in this study. Animal experiments were 
undertaken in full compliance with the UK Home Office regulations and under a 
project license (7009056) to A.C.H. 
 
Isolation of primary IEL 
Human colonic lymphocytes were isolated as previously described22 and used after a 




HEK293T, HT29, CHO (ATCC) and MODE-K cells (a kind gift from Dr. D. 
Kaiserlian, INSERM U1111, Lyon, France) were maintained in DMEM 
supplemented with 4.5 g/L D-glucose, L-glutamine, 10% heat-inactivated fetal calf 
serum (FCS) and 1% penicillin/streptomycin (pen/strep). J76, E6.1 and PAM2.12 
cells were maintained in RPMI 1640 L-glutamine, 10% heat-inactivated FCS, 1% 
pen/Strep. All cell culture reagents were from Thermo Fisher. NFAT-Gaussia 
luciferase (Gluc) reporter cell line JRT331 was maintained in complete RPMI (above) 
supplemented with 0.5 mg/ml G418 (Sigma-Aldrich). For transgenic HEK293T, 
MODE-K, PAM2.12 and CHO cells, medium was supplemented with 1 µg/ml 
Puromycin (Sigma-Aldrich) and/or 500 µg/ml Hygromycin (Thermo Fisher). 
 
Flow cytometry 
Flow cytometry was performed using the following antibodies, coupled to the 
indicated fluorochromes. Antibodies for mouse: CD3ε-APC/Cy7 (145-2C11), γδTCR-
PECy7 (GL3 from eBioscience), γδTCR- PerCPeFluor710 (GL3), γδTCR-PE (GL3), 
γδTCR-BV421 (GL3), Vγ3-BV421 (536 from BD Bioscience), Vγ3-APC (536), Vδ4-
FITC (GL2), TCRβ-BV421 (H57-597), CD25-PerCP/Cy5.5 (PC61), CD122-PE (TM-
β1), CD71-FITC (RI7217), Nur77-PerCPeFluor710 (12.14 from eBioscience). 
Antibodies for human: CD69-AF647 (FN50), CD69-PE (FN50), CD3-FITC 
(UCHT1), CD3-BV421 (OKT3), CD3-BV786 (OKT3), γδTCR-PeCy7 (IMMU510 
from Beckman Coulter), Vδ1-APC (REA173 from Miltenyi), Vδ2-PerCpCy5.5 (B6), 
CD25-BV421 (BC96), CD45RA-PE (HI100). The Vγ2/3/4 biotin (23D12) antibody32 
was detected by conjugation to PE-Streptavidin. Other antibodies: DYKDDDDK-PE 
(Flag), DYKDDDDK-APC (Flag), HA-DyLight 650 (2-2.2.14, Invitrogen), HA-
BV421 (16B12), HA-AF647 (16B12), EPCR-PE (RCR-16), EPCR-APC (RCR-16). 
Antibodies for flow were purchased from Biolegend unless otherwise stated; viability 
dies (Blue or Aqua) were from Invitrogen. Anti-TCRVγ7 producing hybridoma 
(F2.67) was kindly provided by Pablo Pereira (Institut Pasteur, Paris, France).  The 
antibody was purified from hybridoma supernatant using the mouse TCS purification 
system (abcam-ab128749) and conjugated to AF647 (labeling kit, Thermo Fisher 
Scientific). 
Nur77 staining was performed on cells firstly fixed for 10’ with CellFIX (BD 
Bioscience), then fixed and permeabilised using the Foxp3/Transcription factor 
staining buffer set (eBioscience). In one experiment, MODE-K cells were fixed for 
10’ with CellFIX and thoroughly rinsed prior to co-culture assay. 
Flow cytometry data analysis was performed on FlowJo (Version 10).  
 
CD1 protein production and CD1c-PC dextramers 
Plasmids encoding the extracellular domains of human CD1c, and human β2-
microglobulin (β2m) were separately cloned into the prokaryotic expression vector 
pET23d (Novagen). CD1c and β2m were subsequently produced as inclusion bodies 
in Escherichia coli Rosetta strain (Novagen). Inclusion bodies were thoroughly 
washed and fully denatured then reduced in 6 M guanidineHCl and 20 mM DTT 
before in vitro refolding. Refolding of CD1c/β2m complexes was performed by 
oxidative in vitro refolding as previously described56 in the presence of 
Phosphatidylcholine (PC) (Avanti Polar Lipids). Correctly folded proteins were 
purified by size-exclusion chromatography using preparatory grade SD75 26/60 and 
analytical grade SD75 GL 10/300 gel filtration columns (GE Healthcare).  Refolded 
CD1c-PC complexes were biotinylated via an engineered BirA motif at the C 
terminus, repurified by size exclusion chromatography before conjugation to dextran-
PE (Immudex) to generate labelled CD1c-dextramers31. 
 
Co-culture assay 
Co-cultures of murine primary IEL with MODE-K and primary human IEL with 
293T were performed as described previously22. 0.5x105 J76 transductants were 
cultured for 5 h on a confluent monolayer of MODE-K, 293T, CHO and PAM2.12 
previously seeded in 48-well plates. Alternatively, 0.5x105 J76, JRT3 NFAT-GLuc or 
E6.1 transductants were mixed in 96-well plates with either 2x105 MODE-K or 293T 
and co-cultured for 5 h. As control, 0.5x105 J76 cells were stimulated in 96-well 
plates with 10 µg/ml of α-CD3ε (OKT3) or, for the human TCRs, pan-γδTCR (B1), 
and Isotype control IgG (Biolegend). In EPCR blocking experiments, 293T cells were 
pre-incubated with 10 µg/mL α-EPCR or goat IgG (R&D Systems) for 45 min. 
 
Single-cell PCR and sequencing 
A 96-well plate of single cell-sorted responding cells (CD122lowCD25high in mouse 
and TCRlowCD25high in human) was thawed on ice, incubated at 65oC for 5min and 
placed back on ice. The reverse transcription and first round of PCR were performed 
using the qScript XLT One-Step RT-PCR Kit (Quanta Biosciences) following 
manufacturer’s recommendations with slight modifications.  External primers sets 
were used in a 20µL reaction (500nM total concentration for each forward and 
reverse sets). PCR products were then diluted 1:5 for a second round of PCR using 
internal sets of primers and Phusion High-Fidelity DNA Polymerase (NEB). Second 
round PCR products were ran on a 2% agarose gel, bands were excised and purified 
(QIAquick Gel Extraction Kit, Qiagen). Purified amplicons were sent for Sanger 
sequencing to Eurofins Genomics using custom primers. All primers referred to above 




TCR deep sequencing 
Human bulk mRNA was extracted from donor biopsies using AllPrep DNA/RNA 
Mini kit (Qiagen) and sent for γδTCR chain deep-sequencing using the 
IlluminaMiSeq platform with short-read 100/150 PER primers (iRepertoire, 
Huntsville, Alabama, USA). mRNA was extracted from bulk sorted Vγ7+ and Vγ7- 
IEL using the RNA-Micro-plus kit (QIAGEN). Mouse Trgv7 and Trdv genes deep-
sequencing was performed as above. 
 
Plasmids and cloning  
Full-length gamma and delta chains were cloned into the self-inactivating lentiviral 
vector pCSIGPW22, 23 after removal of the IRES-GFP and CMVp-PuroR cassettes. 
Overlap-extension PCR (OE-PCR) was used to replace CDR3 regions with AjuI and 
BaeI restriction sites. Final modified delta chains were subcloned using XhoI/NotI 
(for human constructs) and NcoI/XbaI (for mouse constructs); gamma chain was 
subcloned using NcoI/XbaI (for human constructs) and PmeI/NotI (for mouse 
constructs). Human Vγ9Vδ2 and mouse Vγ5Vδ1 pCSIW constructs were made with 
no restriction sites modifications. Paired CDR3γ/δ sequences were cloned using short 
annealed oligos. Plasmids coding for N-terminus-tagged Btnl/BTNL were described23. 
EPCR was cloned from HT29 cDNA into pCSIGPW using XhoI/NotI restriction sites. 
T22 was cloned from small intestine cDNA of a C57Bl/6 mouse into pCSIGPW using 
PmeI/NotI restriction sites. Mutations to swap CDR/HV4 regions or aminoacids 
(TCRs), solvent-exposed IgV-aminoacids (BTNL3/8) or to remove endogenous 
restriction sites by introduction of silent mutations were all performed by OE-PCR. 
 
 
Lentiviral production and transduction 
All plasmids used for lentiviral transductions were purified using a NucleoBond Xtra 
Midi EF kit (Macherey-Nagel). Lentiviral particles were produced in HEK293T cells 
by co-transfection of pCSIW encoding different TCRs, HIV-1 gag-pol pCR/V157, and 
VSV-G env pHIT/G58. Media was replaced 16 h post-transfection and collected at 48 
h, filtered through 0.45µm nylon mesh and used to transduce 1-2.5x105 J76, E6.1 
JRT3 NFAT-GLuc cells by spinoculation at 1,000 g for 30 min. Cells were assessed 
for TCR expression after 2-5 days. Adherent cell lines were transduced with the 
indicated combinations of FLAG-BTNL3, HA-BTNL8, HA-Btnl6, His-T22 and 
EPCR cloned into pCSIGPW, and FLAG-Btnl1 cloned into pCSIYHW. Viral 
supernatant supplemented with polybrene (1 µg/ml) was added to 50 % confluent 
cells plated 24h prior to transduction. 48h post-transduction, media was supplemented 
with appropriate concentration of antibiotics (Hygromycin and/or Puromycin) and 
when necessary, cells were sorted based on GFP and/or Tag expression. 
 
Co-immunoprecipitation and Mass spectrometry 
Lysates of MODE-K cells transduced with an empty vector (EV) control or with 
Btnl1-FLAG and Btnl6-HA were incubated with anti-DYKDDDDK magnetic agarose 
beads, followed by protein elution and SDS/PAGE. Anti-FLAG immunoprecipitation 
and mass spectrometry analysis were performed as previously described23. 
 
Western blot 
Cell lines were kept overnight in starving media (SM, RPMI 0.5% FBS) harvested, 
washed with SM and allowed to rest in suspension for 1 h at 37oC, 5% CO2. 2.5x105 
JRT3-LES cells were mixed with 6.25x105 stimulatory cells; or 10 µg/mL α-CD3ε 
(UCHT1) and 10 µg/mL pan-γδTCR (B1) crosslinked with anti-mouse IgG 
(Biolegend). Cells were spun down at 600 g for 1 min and incubated at 37˚C. 1 mL 
ice-cold PBS was then added at 5, 10 and 20 min, and spun down 600g, 2min, 4˚C. 
2.5x105 J76-mo8 cells were mixed with 5x105 MODE-K expressing empty vector, 
l1l6 and/or T22; or 10 µg/ml OKT3, UCHT1 and pan-γδTCR (GL3) crosslinked with 
anti-mouse/hamster IgG (Biolegend and Vector laboratories, respectively). Cells were 
spun down at 600 g for 1 min and incubated for 10 min at 37˚C. Pellets were then re-
suspended in 100 µl ice-cold lysis buffer (50 mM Tris, pH 8, 150 mM NaCl, 0.5% 
NP-40, Protease and Phosphatase Inhibitor Cocktail [ThermoFisher]). Lysates were 
incubated for 20 min on ice and spun at 20,000 g for 20 min at 4˚C. Supernatants 
were then mixed with NuPAGE LDS Sample Buffer supplemented with β2-
Mercaptenol (2.5% final concentration) or with 50mM DTT, loaded onto NuPAGE 4-
12% Bis-Tris protein gels (ThermoFisher) and transferred onto nitrocellulose 
membranes. Membranes were then incubated in blocking solution (PBS/TBS, 0.1% 
Tween20, 3% BSA) for 90 min at room temperature and subsequently with primary 
antibodies (1:1000 dilution in blocking solution) overnight at 4˚C. Membranes were 
then washed in PBS/TBS 0.1% Tween20, incubated for 1 hour at room temperature 
with secondary antibodies (1:5000 dilution in blocking solution), washed again and 
developed with Clarity Max Western ECL Blotting Substrate (BioRad) or with ECL 
Western Blotting Detection Reagents (GE Healthcare). Anti CD3ε (#4443), Phospho-
LAT (Tyr191) (#3584), Phospho-PLCγ1 (Tyr783) (#14008/2821), HRP-linked anti-
rat IgG (#7077), HRP-linked anti-rabbit IgG (#7074) and HRP-linked anti-mouse IgG 
(#7076) antibodies were from Cell Signalling Technologies. Anti CD247 (51-6527GR) 
antibody was purchased from BD. 
 
Luciferase assay 
The JRT3 NFAT-Gluc reporter cell line31 was transduced with γδTCRs and 2x105 
cells were co-cultured with 5x105 293T expressing EV or L3L8, or with MODE-K 
expressing EV or l1l6 at 37˚C, 5% CO2. Alternatively, JRT3 lines were stimulated 
with 10 ng/ml PMA (phorbol 12-myristate 13-acetate) and 1 µg/ml ionomycin. After 
24h, supernatants were collected and luciferase activity was measured using the 
BioLux Gaussia Luciferase Assay Kit (NEB) following the manufacturer’s 
instructions. Luminescence was acquired on an EnVision plate-reader (PerkinElmer). 
Background levels were measured from untransduced reporter cell lines.  
 
ELISA assay 
E6.1 cells were transduced with murine γδTCRs and 5x104 cells were co-cultured 
with 2x105 MODE-K expressing EV or l1l6 at 37oC for 24 hours. As control, E6.1 
cells were stimulated with 1 µg/ml of α−CD3ε (OKT3) or IgG2a soluble antibodies. 
After 24h, supernatants were collected and secreted IL-2 was measured using the 
Elisa Max Kit (Biolegend) following the manufacturer’s instructions. 450nm 
absorbance was measured on an Infinite 200 PRO (Tecan) plate reader.  
 
RNAscope 
RNAscope was performed on paraffin embedded sections using probes and kits 
obtained from Advanced Cell Diagnostics using the RNAscope 2.5 HD Duplex 
Assay-RED (performed as single-plex). Probe HS-TRDC-C2 (#433671-C2) was used 
to detected TCRδ chain mRNA. RNAscope. Positive Control Probe - Hs-PPIB-C2 
(#313901-C2). RNAscope Negative Control Probe - Hs-dapB (#310043). 
 
Soluble recombinant TCR 
Soluble γδ TCR heterodimers constructs were generated by fusing γ and δ variable 
domains to β and α constant domains respectively, with a C-terminal addition of the 
heterodimerization motifs Acid-p1 and Base-p159, respectively. A 6xHis-tag was 
added to the resulting δ-α-Base-p1 chain to allow detection using an APC-α-His 
antibody. The CDR3 sequence used for all γ chain constructs was from the Dp10.7 
TCR7. The CDR3 sequence used for both the Vδ1 and Vδ2 constructs was from the 
d1A/B-3 TCR60. Heterodimers were expressed in HEK293 cells and purified using 
size exclusion-high-performance liquid chromatography (SEC-HPLC). All constructs 
were produced and purified by Iontas (Cambridge, UK).  
  
Modelling software code availability 
3D-JIGSAW and SwarmDock were used to generate 3D models of proteins and 
perform docking simulations, respectively. The full source codes have not been 
released. Publicly available servers for 3D-JIGSAW and SwarmDock can be accessed 




GraphPad Prism (version 7) was used to perform statistical analysis. P values were 
determined by paired two-tailed Student’s t-tests. n values and error bars are defined 





Additional information on study design and reagents is available in the Reporting 
Summary linked to this article. 
 
Data availability 
This work did not include any data with mandated deposition in public databases. 
Associated raw data are provided in the main and/or supplementary figures. Relations 
to summary data charts are indicated and a full list of figures with associated raw data 
is provided in the Reporting Summary linked to this article. 
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Figure 1. Primary Vγ7+ IEL exhibit a semi-invariant TCR usage. 
a, TCR deep-sequencing analysis of Vγ7 CDR3 length distribution (number of amino 
acids) of sorted Vγ7+ cell RNA. Data are expressed as the relative proportion of reads 
for each length, pooled from three independent sorts from pooled mice IEL (n = 12). 
Relative amino acid composition is shown for the most common length (13) using 
WebLogo (black, hydrophobic; green, basic; red, acidic; blue, polar). b, TCR deep-
sequencing data from (a) analysed to determine Trdv gene usage by Vγ7+ cells. Data 
derived from Vγ7+ cells sorted from pooled mice IEL (n = 4). Representative of three 
independent sorts. c, TCR deep-sequencing data from (a) was further analysed to 
determine Vδ7, Vδ2-2, and Vδ6D-1/2 CDR3 length distribution and composition for 
the most common length (16, 16 and 13, respectively), as in (a). d, Flow cytometry 
analysis of CD25 (left) and CD122 (centre) expression by primary Vγ7+ IEL after co-
culture with MODE-K.EV or MODE-K.l1l6 cells overnight. Data expressed as 
mean±s.d. of the proportion of positive Vγ7+ IEL (CD25) or gMFI of Vγ7+ IEL 
(CD122) in individual co-cultures (n = 4). Corresponding examples of raw flow 
cytometry plots are shown (right). Representative of five experiments. e,f, Flow 
cytometry analysis of CD3 (e) and CD71 (f) expression by Vγ7+ IEL after co-culture 
with MODE-K.EV or .l1l6 cells. Data expressed as mean±s.d. of gMFI in co-cultures 
from individual mice (n = 4). Corresponding examples of raw flow cytometry plots 
are shown (right). Representative of five (CD3) and two (CD71) experiments. *P < 




Figure 2. Expression of murine Vγ7 TCR confers responsiveness to Btnl1+Btnl6. 
a, Flow cytometry analysis of γδTCR, and Vγ7 or Vγ5 expression on J76 cells 
transduced with the indicated TCRs, 72 h post-transduction. Representative of 2 
independent transductions. b, Flow cytometry analysis of γδTCR and CD69 
expression by J76 cells transduced with the indicated TCRs and co-cultured with 
control IgG, α-CD3e (OKT3), MODE-K.EV, or MODE-K.l1l6 for 5 h. 
Representative of three independent experiments. c, Flow cytometry analysis of TCR 
downregulation (left) and CD69 upregulation (right) by J76 cells transduced with the 
indicated TCRs (see Table 1 for details) and co-cultured with MODE-K.l1l6 or α-
CD3ε for 5 h. Data expressed as mean±s.d., normalized to MODE-K.EV and control 
IgG, respectively; pooled from three independent experiments. d, Flow cytometry 
analysis of Nur77 expression (left) by J76-mo5 cells co-cultured with the indicated 
antibodies or cell lines for 2 h. Data expressed as mean±s.d. of the proportion of 
Nur77+ cells; pooled from three experiments. Corresponding examples of raw flow 
cytometry contour plots are shown (right).  *P < 0.05, **P < 0.01, ***P < 0.001. 
 
Figure 3. Expression of human Vγ4 TCR confers responsiveness to 
BTNL3+BTNL8. 
a, RNAscope analysis of TCRδ (TRDC, left), dihydropicolinate reductase (dapB, 
centre; negative control), or Peptidyl-prolyl Isomerase B (PPIB, bottom; positive 
control) expression in paraffin-embedded human colon sections. Scale bars, 1 mm. 
Representative of biopsies from multiple donors (n = 3). b, Flow cytometry analysis 
of TCR downregulation (top) and CD25 expression (bottom) by human colonic 
lymphocytes after co-culture with 293T.EV or 293T.L3L8 cells overnight. TCR 
downregulation data expressed as mean±s.d. of independent co-cultures from multiple 
donors (n = 11) with 293T.L3L8 cells, normalized to 293T.EV cells. CD25 data 
shown as the paired proportion of CD25+ cells within Vγ2/3/4+ cells in lymphocytes 
co-cultured with the indicated cell lines for each donor (n = 11). *P < 0.05, **P < 
0.0001. c, Flow cytometry analysis of Vγ2/3/4 and γδTCR (donor 1), or Vγ2/3/4 and 
CD25 (donors 2 and 3) expression by human colonic lymphocytes after co-culture 
with the indicated cell lines overnight. Gates used for single-cell sorting are shown. 
Pre-gated on singlets/live/CD3+Vδ2-/γδTCR+ cells. d, Flow cytometry analysis of 
γδTCR and CD69 expression by J76-hu17 cells (see Table 2 for details) and co-
cultured with the indicated antibodies or cell lines for 5 h. Representative of three 
independent experiments. e, Flow cytometry analysis of TCR downregulation (left) 
and CD69 upregulation (right) by J76 cells transduced with the indicated TCRs (see 
Table 2) and co-cultured with 293T.L3L8 or α-CD3ε (OKT3) for 5 h. Data expressed 
as mean±s.d. of individual co-cultures (n = 3), normalized to 293T.EV and control 
IgG respectively. Representative of three independent experiments. 
 
Figure 4. Human Vγ4HV4 is a critical determinant of the response to BTNL3+8. 
a, Alignment of human TCR Vγ chain amino acid sequences (divergence from Vγ4 in 
red). Variable regions are highlighted (green, CDR1; yellow, CDR2; pink, HV4; blue, 
CDR3). Horizontal arrow delineates Framework Region 3 (FR3). b,c,d, Flow 
cytometry analysis of TCR downregulation (x-axis) and CD69 upregulation (y-axis) 
by J76 cells transduced with hu17 or the indicated variants (see Supplementary Fig. 
4a,b,c,d) and co-cultured with 293T.L3L8 for 5 h. Data expressed as mean±s.d. of 
individual co-cultures (n = 3), normalized to 293T.EV. Representative of two (b), 
three (c) and four (d) independent experiments. 
 
Figure 5. Cross-species conservation of the critical role of HV4γ  in the response 
to Btnl/BTNL. 
a, Alignment of mouse Vγ7 and Vγ6 sequences (top), and of mo5 variants (bottom, 
differences from wild-type Vγ7 sequence in red). Due to space constraints the most C-
terminal region sequence (YYCASWA, identical between all constructs), is not 
depicted. CDR1/2/3 regions are highlighted in green, yellow and cyan, respectively. 
b,c, Flow cytometry analysis of TCR downregulation (x-axis) and CD69 upregulation 
(y-axis) by J76 cells transduced with mo5 or the indicated variants (see 
Supplementary Fig. 5a,b,c,d) and co-cultured with MODE-K.l1l6 for 5 h. Data 
expressed as mean±s.d. of individual co-cultures (n = 3), normalized to MODE-K.EV. 
Representative of four independent experiments. d, Flow cytometry analysis of TCR 
downregulation (left) and CD69 upregulation (centre) by J76 cells transduced with the 
indicated TCRs and co-cultured with 293T.l1l6 or 293T.L3L8 for 5 h. Data expressed 
as mean±s.d. of individual co-cultures (n = 3), normalized to 293T.EV. 
Corresponding raw flow cytometry plots are shown (right). Representative of four 
independent experiments. *P < 0.01, **P < 0.001.  
 
Figure 6.  A proposed model for BTNL3 engagement by Vγ4+ TCRs. 
a, Flow cytometry analysis of TCR downregulation (top) and CD69 upregulation 
(bottom) by J76-hu17 co-cultured with the indicated stimulants. Data expressed as 
mean±s.d. of individual co-cultures (n = 3), normalized to 293T.EV. Representative 
of three independent experiments. b, Heterodimeric model of BTNL3 (green) / 
BTNL8 (teal), derived with 3D-JIGSAW from a BTN3A1 homodimer (PDB 4F80). 
Candidate motifs (see Supplementary Fig. 6c,d) are highlighted in orange, yellow, 
blue and red. c, Flow cytometry analysis of TCR downregulation (top) and CD69 
upregulation (bottom) by J76-hu17 cells co-cultured with the indicated 293T 
transfectants for 5 h. Data expressed as mean±s.d. of individual co-cultures (n = 3), 
normalized to EV. Representative of three independent experiments. d, SwarmDock 
best-fit of TCR Vγ4 V-domain (light grey, PDB 4MNG) docking to BTNL3 IgV-
domain (green). Motifs validated by functional assays (see Fig. 4c; Fig. 6c) are 
highlighted (TCR Vγ4: pink [HV4γ]; BTNL3: orange [NQFHA], blue [WF], red 
[DEEAT]) with side-chains displayed. e, Flow cytometry analysis of the indicated 
soluble TCRs (sTCR; pre-incubated with α-His antibody) binding to 293T.EV or 
293T.L3L8 cells after incubation at 4˚C for 1 h. Representative of three independent 
experiments. f, Flow cytometry analysis of the indicated sTCR+α-His stainings. Data 
expressed as gMFI mean±s.d. of individual stainings (n = 3), normalized to α-His 
alone. g, Flow cytometry analysis of TCR downregulation (top) and CD69 
upregulation (bottom) by J76-mo5 co-cultured with the indicated 293T transfectants 
for 5 h. Data expressed as mean±s.d. of individual co-cultures (n = 3), normalized to 
empty vector transfectants. Representative of three independent experiments. 
 
Figure 7. Human Vγ4+ and mouse Vγ7+ TCRs exhibit dual-reactivity. 
a, SwarmDock model showing the crystal structure of a Vγ4Vδ1 TCR binding CD1d-
sulfatide (PDB 4MNG) docking to the complete BTNL3/BTNL8 heterodimer model 
(Fig. 6b). The docking solution is derived from Fig. 6d. b, Flow cytometry analysis of 
TCR downregulation (left) and CD69 upregulation (right) by JRT3 cells transduced 
with LES or hu12 TCRs and co-cultured with the indicated cell lines or α-CD3ε 
(OKT3) for 5 h. Data expressed as mean±s.d. of individual co-cultures (n = 3), 
normalized to 293T.EV or control IgG respectively. Representative of two 
independent experiments. c, Flow cytometry analysis of CD3ε and γδTCR expression 
(left), and staining with Streptavidin alone (center) or pre-incubated with CD1c-PC 
(right) on J76 cells transduced with hu17 or hu20 TCRs. Representative of three 
experiments. d, Flow cytometry analysis of TCR downregulation (left) and CD69 
upregulation (right) by J76 cells transduced with hu17 or hu20 TCRs and co-cultured 
with 293T.L3L8 cells or α-CD3ε for 5 h. Data expressed as mean±s.d. of individual 
co-cultures (n = 3), normalized to 293T.EV or control IgG, respectively. 
Representative of three independent experiments. e, Flow cytometry analysis of TCR 
downregulation (left) and CD69 upregulation (right) by J76 cells transduced with the 
mo8 (T22-specific) or mo5 (control) Vγ7+ TCRs and co-cultured with the indicated 
cell lines for 5 h. Data expressed as mean±s.d. (n = 3), normalized to MODE-K.EV or 
293T.EV. Representative of five independent experiments. *P < 0.05, **P < 0.01, 
***P < 0.001. 
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Table 1. Murine γδTCR chain pairs used for T cell transduction.  
Amino acid sequences (non-germline in red) of the CDR3γ and δ pairs cloned into 
lentiviral vector (LV) backbones. Corresponding frequencies (freq.) and ranks for 



















 CDR3γ  CDR3δ  
Clone V usage AA sequence Freq. average [indep. pools] 
Ranks in 
indep. Pools AA sequence 
Freq. average 
[in indep pools] 
Ranks in 
indep. Pools 
mo1 Vγ7Vδ6D2 ASWAYSSGFHKV 5.2%  [5.5 / 5.7 / 4.3]  3 / 2 / 4 ALSEPWHIGGIRATDKLV 
0.04%  
[0.03 / 0.09 / 0] 403 / 189 / n.f. 
mo2 Vγ7Vδ6D2 ASWADSSGFHKV 2.8%  [2.9 / 2.7 / 2.9]  7 / 8 / 9 ALSELSEGYEPATDKLV 
0  
[0 / 0 / 0] n.f. / n.f. / n.f. 
mo3 Vγ7Vδ2-2 ASWARYSSGFHKV 1.3%  [1.2 / 1.2 / 1.4] 21 / 21 / 14 ALMGIGGLATDKLV 
0.002%  
[0 / 0 / 0.006] n.f. / n.f. / 1177 
mo4 Vγ7Vδ2-2 ASWAGYSSGFHKV 20.3%  [17.8 / 22.8 / 20.0]  1 / 1 / 1 ALMERGTEGYATDKLV 
0.0007%  
[0 / 0.002 / 0] n.f. / 3544 / n.f. 
mo5 Vγ7Vδ2-2 ASWAGYSSGFHKV 20.2%  [17.8 / 22.8 / 20.0]  1 / 1 / 1 ALMERGRRDTSLTDKLV 
0.013%  
[0 / 0.04 / 0] n.f. / 279 / n.f. 
mo6 Vγ7Vδ7 ASWALSSGFHKV 0.03%  [0.007 / n.f. / 0.08] 
366 / n.f. / 
108 AMGYRRDTDKLV 
0.75%  
[1.5 / 0.002 / 0.8] 8 / 2066 / 25 
mo7 Vγ7Vδ7 ASWGYSSGFHKV 5.4%  [5.8 / 4.5 / 5.8]  2 / 3 / 2 AMGATDKLV 
0.2%  
[0 / 0.6 / 0] n.f. / 16 / n.f. 
	
	
Table 2. Human γδTCR chain pairs used for T cell transduction.  
Amino acid sequences (non-germline in red) of the CDR3γ and δ sequenced from 
colonic IELs responding to BTNL3+8 (donors 1-3, hu1-19; see Fig. 3), with 
corresponding frequencies (freq.) and ranks in the corresponding deep-sequencing 
data (n.f, not found); from colonic IELs stained by CD1c-PC dextramers (donor 4, 
hu20; see Fig. 7); from peripheral blood γδ lymphocytes (donor 5, huPB), and from 
skin-derived IEL (donor 6, sk1-2; see Supplementary Fig. 7c). Lymphocytes isolated 
from donors 4-6 were not subjected to deep sequencing (N/A, not applicable). 
 
   CDR3γ  CDR3δ  
Donor Clone	 V usage AA sequence Freq.  Rank AA sequence Freq.  Rank 
1 
hu1 Vγ4Vδ1 ATWDPGWFKI 0 n.f ALGEIGYWGIHRVNKLI 0 n.f 
hu2 Vγ4Vδ3 ATWDWGYYKKL 0 n.f ASGDTTDKLI 0 n.f 
hu3 Vγ4Vδ3 ATWAGYYKKL n.f n.f AAMGVPFLEGDTGPKLI  0 n.f 
hu4 Vγ2Vδ1 ATWKSSDWIKT n.f n.f ALGELGYPDKLI 0.02% 1118 
2 
hu5 Vγ4Vδ1 ATWDGACTTGWFKI  n.f n.f ALGEKMGPNKLI 0 n.f 
hu6 Vγ4Vδ1 ATWDGACTTGWFKI n.f n.f ALGPYRVRLIDKLI 0 n.f 
hu7 Vγ4Vδ1 ATWDGPWNYYKKL 0.13% 88 ALGERGYWGILGDKLI 0 n.f 
hu8 Vγ4Vδ3 ATWAPYYKKL 0.21% 49 AFCSVYWGICTDKLI 3.3% 6 
hu9 Vγ4Vδ3 ATWDGPNYKKL  11% 2 AFFFGWGIRFYTDKLI 42.7% 1 
3 
hu10 Vγ4Vδ3 ATWETYYKKL 3.4% 4 AFMFPPVGGLLI 36.6% 1 
hu11 Vγ4Vδ1 AIANYYKKL 0.04% 216 ALGELLYVGGIIDKLI 0 n.f 
hu12 Vγ4Vδ1 ATWVMAHYKKL 3.6% 3 ALGERESLYKLI 7.5% 2 
hu13 Vγ4Vδ1 ATWDGPVL  0.8% 17 ALGESTGPYWGIRGYTDKLI 2.0% 13 
hu14 Vγ4Vδ1 ATWVPGWFKI 0.44% 36 ALGELREWGTGVYTDKLI 1.2% 18 
hu15 Vγ4Vδ1 ATWDGRGATGWFKI 0.63% 28 ALGCQYWGIQADKLI 2.2% 12 
hu16 Vγ2Vδ3 ATWDGPHYKKL 10.4% 2 AFMFPPVGGLLI 36.6% 1 
hu17 Vγ4Vδ1 ATWDGSKKL 0.2% 72 ALGESSLGYWGILADKLI 0 n.f 
hu18 Vγ4Vδ1 ATWDAFGWFKI 0 n.f ALGELELRLKIPGTDKLI 3.9% 6 
hu19 Vγ4Vδ3 ATWDCRYKKL 0 n.f AFLPYWGIRKGSDTLTDKLI 0 n.f 
4 hu20 Vγ4Vδ1 ATWDGYKKL N/A N/A ALGPPLFYVLGYRKLI N/A N/A 
5 huPB Vγ9Vδ2 ALWEKQQELGKKIKV N/A N/A ACDPLGNQYTDKLI N/A N/A 
6 
sk1 Vγ4Vδ1 ATWELNYYKKL N/A N/A ALGTIRPSPFLLGGYLTRTTDKLI N/A N/A 
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Supplementary Fig. 1. Delta chain usage of  Vγ7- IEL, and Btnl1+6 co-precipitation 
 
a, TCR analysis of Trdv gene usage by Vγ7- IEL sorted in parallel to the Vγ7+ IEL from Fig. 1a,b,c. Data derived from cells sorted from pooled mice IEL (n = 8). 
Representative of three independent sorts. b, Volcano plot representation of a mass-spectrometry analysis following anti-Flag pull-down on lysates from MODE-
K.EV or MODE-K.l1l6 cells. Data expressed as the mean Welch difference in protein intensities in MODE-K.l1l6 versus MODE-K.EV samples (x-axis; Welch 
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Supplementary Fig. 2. Requirements for a Btnl1+6-dependent response. 
 
a, Flow cytometry analysis of the proportion of CD69+ J76-mo5 cells (y-axis) co-cultured with α-CD3ε or MODE-K.l1l6 over time (x-axis). Data expressed as  
mean of two experiments. b, Quantification of NFAT promoter activity (left) in JRT3.NFAT-GLuc cells transduced with the indicated TCRs and co-cultured with 
MODE-K.EV or MODE-K.l1l6 cells for 24 h. Gaussia Luciferase (GLuc) was measured in supernatants (RLU/s, relative light units per second). Data expressed as 
mean±s.d. (n = 3) and representative of two experiments. Cells were analysed in parallel by flow cytometry for γδTCR and CD69 expression (right) as a positive 
control of the response to MODE-K.l1l6 cells. c, Flow cytometry analysis of TCR downregulation (left), CD69 upregulation (centre) and ELISA quantification of 
IL-2 production (right) by E6.1-mo5 cells co-cultured with the indicated antibodies or cells lines. Flow cytometry data acquired after 5 h, expressed as mean±s.d., 
normalized to IgG or MODE-K.EV; pooled from nine independent experiments. ELISA data acquired after 24 h, expressed as mean±s.d. (n = 3); representative of 
three experiments. d, Flow cytometry analysis of TCR downregulation (left) and CD69 upregulation (right) by J76-mo5 cells co-cultured with untouched (control) 
or fixed MODE-K.l1l6 cells for 5 h. Data expressed as mean±s.d., normalized to MODE-K.EV; pooled from three independent experiments. e, Flow cytometry 
analysis of TCR downregulation (top) and CD69 upregulation (bottom) by J76-mo1, -mo5 or -moD cells co-cultured the indicated cell lines transduced with 
Btnl1+6. Data expressed as mean±s.d., normalized to corresponding cell line transduced with empty vector; pooled from three independent experiments. f, Flow 
cytometry analysis of the proportion of CD25+ cells in Vγ7+ IEL co-cultured with the indicated cell lines overnight. Data from individual mice expressed as 
mean±s.d. (n = 3). g, Flow cytometry analysis of CD25, CD122 and CD3ε expression by Vγ7+ IEL co-cultured with the indicated cell lines transduced with EV or 


































































































































































































































































































Supplementary Figure 3. The transfer of Vγ4+ TCRs from responding IELs confers reactivity to BTNL3+8. 
	
a, Flow cytometry analysis of colonic γδ T cell composition, as proportion of total CD3+ cells (top); Vγ2/3/4 chain usage of TCRγδ+Vδ2- cells and Vδ chain usage 
of Vδ2-Vγ2/3/4+ cells (bottom), after a 5 days culture. Data expressed as mean±s.d. of independent patient biopsies (n = 11). b, Flow cytometry analysis of CD3 
and CD25 expression by the indicated human colonic lymphocyte subsets after co-culture with 293T.EV (grey) or .L3L8 (red) overnight. Representative of 
independent patient samples (n = 11). c, Flow cytometry analysis of CD3ε and γδTCR expression by J76 cells transduced with the indicated TCRs, 96h post-
transduction. Representative of three independent experiments. d, Flow cytometry analysis of TCR downregulation (left) and CD69 upregulation (centre) by J76-
hu12 cells co-cultured with the indicated cells lines or α-γδTCR antibody for 5 h. Data expressed as mean±s.d (n = 3), normalized to the matching cell lines 
transduced with empty vector, or control IgG.  Corresponding raw flow cytometry plots are shown on the right. Representative of two (J76) or three (MODE-K) 
independent experiments (293T). e, Quantification of NFAT promoter activity (left) in JRT3.NFAT-GLuc cells transduced with the indicated TCRs and co-cultured 
with 293T.EV or 293T.L3L8 cells, or stimulated with PMA and ionomycin (PMA+iono) for 24 h. Gaussia luciferase (GLuc) was measured in supernatants (RLU/s, 
relative light units per second). Data expressed as mean±s.d (n = 3); n.d, non-detectable above background. Cells were analysed in parallel by flow cytometry for 
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Supplementary Fig. 4. hu17 TCR variants and their responses to L3L8 
	
a, Alignment of hu17 variants tested in Fig. 4b,c,d. Differences from the wild-type Vγ4 sequence are in bold red. CDR1/2/3 and HV4 are highlighted in green, 
yellow, cyan and pink, respectively. b,c,d, Flow cytometry analysis of γδTCR and CD69 expression by J76 cells transduced with the indicated hu17 TCR variants 
and co-cultured with 293T.EV or 293T.L3L8 cells for 5 h. Representative of individual co-cultures (n = 3), related to Fig. 4b,c,d. e, Quantification of NFAT 
promoter activity (left) in JRT3.NFAT-GLuc cells transduced with the indicated hu17 TCR variants and co-cultured with 293T.EV or 293T.L3L8 cells for 24 h. 
GLuc was measured in supernatants (RLU/s, relative light units per second). Data expressed as mean±s.d. of individual co-cultures (n = 3). *P < 0.05; **P < 0.01; 
ns, not significant. Cells were analysed in parallel by flow cytometry for γδTCR and CD69 expression (right) as a positive control of the response to 293T.L3L8 
cells.  
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Supplementary Fig. 5. HV4 is required for responses to human and murine BTNL/Btnl 
	
a, Flow cytometry analysis of Vγ7 and γδTCR expression by J76 cells transduced with the indicated TCRs and sorted to ensure equivalent expression. 
Representative of three independent experiments. b, Flow cytometry analysis of γδTCR and CD69 expression by J76 cells transduced with the indicated TCRs and 
co-cultured with MODE-K.EV or MODE-Kl1l6 cells for 5 h. Representative of individual co-cultures (n = 3), related to Fig. 5b. c, Alignments of mouse Vγ7 with 
human Vγ4 sequences (top; amino acids identified in Fig. 4c are bolded); and of mo5 variants tested in Fig. 5c,d (bottom; differences from wild-type Vγ7 sequence 
in bold red). d, Flow cytometry analysis of γδTCR and CD69 expression by J76 cells transduced with the indicated mo5 variants and co-cultured with MODE-
K.EV or MODE-K.l1l6 cells for 5 h. Representative of  individual co-cultures (n = 3), related to Fig. 5c.	
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Supplementary Figure 6. Stepwise determination of the Vγ4 / BTNL3 interaction model 
 
a, Cartoon representation of the crystal structure of a Vγ4Vδ1 TCR V-domains (from PDB 4MNG), with all CDRs and HV4γ highlighted. b, Cartoon 
representation of a BTNL3 (green) / BTNL8 (teal) heterodimer model, derived with 3D-JIGSAW from a BTN3A1 homodimer (PDB 4F80). c, Alignment of the 
IgV-domain sequences of BTNL3 and BTNL8. Canonical Ig-fold β-strands [A,B,C,C’,C”,D,E,F,G] are indicated with arrows. Solvent-exposed residues that are 
significantly different are highlighted in orange [NQFHA/GQFSS], yellow [EDWESK/KDQPFM], blue [WF/RI], and red [DEEAT/YQKAI]. d, Cartoon 
representation of the IgV-domains of BTNL3 (green) and BTNL8 (teal) from (b), with the same annotation as in (c). e, Cartoon representation of the results of 200 
unrestricted docking simulation runs in SwarmDock, between the IgV-domain of BTNL3 (green) and the TCR Vγ4Vδ1 V-domains (PDB 4MNG). Each sphere 
represents the centroid of the TCR (numbers in italic indicate the number of solutions for groups) and are color-coded according to the relative energy between the 
docked poses (relative Docking Complex [DComplex] Energy Potential scale displayed on the right). Note that the IgV-domain of BTNL3 is rotated 45˚ counter-
clockwise along the x-axis compared to (d). f, Flow cytometry analysis of FLAG-tagged BTNL3 and HA-tagged BTNL8 expression in 293T cells, 48 h post-
transfection. Representative of three independent experiments. Related to Fig. 6c. g, Flow cytometry analysis of the binding of the indicated soluble TCRs (sTCR; 
pre-incubated with anti-6xHis tag antibody, α-His) after incubation with MODE-K.EV or MODE-K.L3L8 cells at 4˚C for 1 h. Representative of three independent 
experiments.  Related to Fig. 6e. h, Flow cytometry analysis of FLAG-BTNL3 and HA-BTNL8 expression on the indicated cell lines that were used for the sTCR 
staining experiments. Related to (g) and Fig. 6e. i, Surface representation of a heterodimeric Btnl1 (green) / Btnl6 (teal) model, derived with 3D-JIGSAW from a 
BTN3A1 homodimer (PDB 4F80). Candidate CFG face motifs corresponding to the ones identified in BTNL3 (see Fig. 6b,c; and below) are highlighted in orange 
(AQPTP/SRFSA), blue (QF/HF), and red (SQEVS/YEEAI). j, Alignment of the IgV-domain sequences of BTNL3, Btnl1 and Btnl6. Canonical Ig-fold β-strands 
[A,B,C,C’,C”,D,E,F,G] are indicated with arrows. Candidates motifs are highlighted using the same colour-coding as in (i). k, Flow cytometry analysis of γδTCR 
and CD69 expression by J76-mo5 cells co-cultured with 293T cells expressed the indicated constructs for 5h. Representative of three independent experiments. 
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Supplementary Figure 7.  Dual reactivity of human and mouse γδTCRs 
	
a, Flow cytometry analysis of CD69 upregulation (left) by JRT3-LES cells co-cultured with the indicated cell in the presence of control IgG or α-EPCR antibodies 
(10 µg/mL) for 3 h. Data expressed as mean±s.d. of the proportion of CD69+ cells in individual co-cultures (n = 3). Corresponding raw flow cytometry plots are 
shown (right). Representative of two independent experiments. *P < 0.001; n.s, not significant. b, Western blot analysis of PLCγ and LAT phosphorylation in 
JRT3-LES cells co-cultured with the indicated cell lines or antibodies at 37˚C for the indicated times. CD3ε, loading control. Representative of three independent 
experiments. c, Flow cytometry analysis of TCR downregulation (left) and CD69 upregulation (centre) by J76 cells transduced with the indicated TCRs and co-
cultured with 293T.L3L8 cells or α-CD3ε. Data expressed as mean±s.d. of individual co-cultures (n = 3), normalized to 293T.EV or control IgG. Corresponding 
examples of raw flow cytometry plots are shown (right). Representative of three independent experiments. d, Flow cytometry analysis of CD1c-PC dextramer 
binding to human colonic γδTCR+ cells. The gate used for single-cell sorting is shown. e, Flow cytometry analysis of γδTCR and CD69 expression by J76-mo8 and 
J76-mo5 cells after co-culture with the indicated cell lines. Representative of three individual co-cultures, related to Fig. 7e. e, Western blot analysis of PLCγ and 
LAT phosphorylation in J76-mo8 cells co-cultured with the indicated cell lines or antibodies at 37˚C for 10 min. CD247, loading control. Representative of three 






V usage Clone # CDR3γ CDR3δ 
Vγ7Vδ7 
1 A S W R Y S S G F H K V A M L A T D K L V  
2 (mo7) A S W G Y S S G F H K V A M G A T D K L V  
3 A S W G Y S S G F H K V A I Y R F T D K L V  
4 A S W G R Y S S G F H K V A I Y R S T D K L V  
5 A S W A Q Y S S G F H K V A V G W G D K L V 
6 A S W A Y S S G F H K V  A M G R D N A K L V 
7 A S W V Y S S G F H K V A P S T T A T D K L V  
8 A S W G Y S S G F H K V A W G I R A T D K L V 
9 A S W A G L S S G F H K V A W G I R A T D K L V 
10 A S W A E Y S S G F H K V A W G I R A T D K L V 
11 A S W A G Y S S G F H K V A M P R D A T D K L V  
12 A S W A G Y S S G F H K V  A M G R G T T D K L V 
13 A S W A P Y S S G F H K V  A R I S E G Y D D K L V 
14 A S W E Y S S G F H K V  A Y R R D T S T D K L V 
15 A S W A E G G Y S S G F H K V  A C L Y R R D T D K L V 
16 A S W A L Y S S G F H K V A M V G G I R V D K L V 
17 (mo6) A S W A L S S G F H K V A M G Y R R D T D K L V 
18 A S W A Y S S G F H K V A M L P R D T S S D K L V 
19 A S W G Y S S G F H K V A T Y R R D T G T D K L V 
20 A S W A H S S G F H K V A M V P Y R R D T D K L V 
21 A S W A G R G S S G F H K V A M V D I G G I N T D K L V 
22 A S W A Y S S G F H K V  A M E R I S E G Y E L G K L V 
23 A S W A E Y S S G F H K V A M E Q V A G G I R T D K L V 
24 (mo8) A S W A G Y S S G F H K V A M E R W E G Y E L T D K L V 
25 A S W E Y S S G F H K V  A M A I Y R R D T R A T D K L V 
Vγ7Vδ2-2 
26 A S W A G G G S S G F H K V A L L E G P L S S D K L V 
27 A S W T Y S S G F H K V A L M A S E G Y A D K L V 
28 A S W A G Y S S G F H K V A L M E R G R G I A D K L V 
29 (mo3) A S W A R Y S S G F H K V A L M G I G G L A T D K L V 
30 A S W A G G G S G F H K V A L M E R G E G Y E I T D K L V 
31 (mo4) A S W A G Y S S G F H K V A L M E R G T E G Y A T D K L V 
32 A S W A V Y S S G F H K V A L M E R G T E G Y E L S D K L V 
33 (mo5) A S W A G Y S S G F H K V A L M E R G R R D T S L T D K L V 
34 A S W A G P L Y S S G F H K V  A L M E R V G G I R A W S D K L V  
35 A S W A G G S S G F H K V A I M E G G A Y R R D T S S D K L V 
36 A S W A G D S S G F H K V A L M E R V G G I R V P C P D K L V  
37 A S W A L Y S S G F H K V A L M E R Y I G G I R A W G T D K L V 
38 A S W A G Y S S G F H K V A L M E R G L Y R R D T S L G D K M V  
Vγ7Vδ6D2 
39 A S W A D S S G F H K V A L S E Q G H I Y T T D K F V 
40 (mo2) A S W A D S S G F H K V A L S E L S E G Y E P A T D K L V 
41 A S W A G Y S S G F H K V A L S E L I L T G G I R A T D K L V 
42 (mo1) A S W A Y S S G F H K V  A L S E P W H I G G I R A T D K L V 
43 A S W A G Y S S G F H K V A L S E L I G A Y R R D T S S D K L V 
	
	
Supplementary Table 1. Murine γδTCR chain pairs identified through the single-cell analysis  
Paired CDR3γ/δ amino acid sequences (red, non-germline-encoded) identified by single-cell TCR 
sequencing of Btnll+6-responding murine primary Vγ7+ IEL. Paired sequences for which both CDR3γ 














































Supplementary Table 2. List of primers used in this study. 
All sequences read 5’ to 3’. For cloning of the human Vγ chains downstream of the IRES an 
NcoI restriction site (C^CATGG) was introduced by mutating the first nucleotide 
downstream of the start codon (bold red).		
Single cell PCR 
External primer sets 
mVγ7  For ATGCTGTGGGCTCTGG 
mCγ1      Rev TTAGGATTTCTTCTCATTGCCACAG 
mVδ2-2  For ATGGTGCGGCCGTTC 
mVδ6D  For ATGGCTCCTCAGAGCCTG 
mVδ7  For ATGGAGAGGCTGCTGTGCTCTC 
mCδ  Rev TTACAAGAAAAATAACTTGGCAGTCAAGAG 
hVγ2/3/4 For ATGGAGTGGGCCCTAGCG 
hCγ1/2  Rev TTATGATTTCTCTCCATTGCAGCAG 
hVδ1  For ATGCTGTTCTCCAGCCTGCTG 
hVδ3  For ATGATTCTTACTGTGGGCTTTAGCTTTTTG 
hCδ  Rev TTACAAGAAAAATAACTTGGCAGTCAAGAG 
Internal primer sets 
mVγ7  For TGAAGGCCCGGACAAGAG 
mCγ1 Rev TGTGCTCTTTCCCCATTGC 
mVδ2-2 For TGCAACGTTAAACCGCTTCTC 
mVδ6D  For AAATCCATCAGCCTTGTCATTTC 
mVδ7 For AAGCACACTGGAAGACTGACATCC 
mCδ Rev GTCGAATTCCACAATCTTCTTGG 
hVγ2-8  For CACTGGTACCTACACCAGGAGG 
hCγ1/2 Rev GGAGGAGGTACATGTAATATGCAGAG 
hVδ1 For GGTACAAGCAACTTCCCAGCAAAG 
hVδ3  For ACCGGATAAGGCAAGATTATTCC 
hCδ  Rev GGCAGCTCTTTGAAGGTTGC 
Other cloning primer sets 
mVγ5 For ATGTCAACCTCTTGGCTTTTTC 
mVδ1 For ATGCTTTGGAGATGTCCAGTC 
hVγ9 For ATGGTGTCACTGCTCCACACATC 
hVδ2 For ATGCAGAGGATCTCCTCCCTCAT 
EPCR For GGAGCCTCAACTTCAGGATG 
EPCR Rev TTAACATCGCCGTCCACC 
T22 For ATGTCCTGGGTCCTCAGGG 
T22 Rev TCAAGGTGACAGTAAAGACTCGCC  
Sequencing primers 
mCγ1 Rev CCAGGATAGTATTGCCATCC 
mCδ Rev CAGACAAGCAACATTTGTTCC 
hCγ Rev GCAGTAGTGTATCATTTGCATC 
hCδ Rev GGTTTTACGTGATCTGTAGAATCTGTC 
